Abstract
The obesity epidemic has a direct impact on every aspect of health. Current strategies to treat obesity are limited and there is a need to pioneer novel solutions. Anorectic gut hormones, physiologically secreted post-prandially to mediate satiety, have recently emerged as potential therapeutic targets in obesity. Peptide tyrosine tyrosine (PYY) is one such anorectic gut hormone, secreted from entero-endocrine L cells, which acts on neuropeptide Y (NPY) receptors within the central appetite circuit. Since the first intravenous administration of PYY to man nearly a decade ago, a number of translational studies and clinical trials have ensued with a view to developing this peptide as a treatment for obesity. This review reports on the current state of play of this on-going research.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Anti-Obesity Agents / administration & dosage
-
Anti-Obesity Agents / pharmacology
-
Anti-Obesity Agents / therapeutic use*
-
Appetite Depressants / pharmacology
-
Appetite Depressants / therapeutic use
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / pharmacology
-
Gastrointestinal Agents / therapeutic use
-
Humans
-
Molecular Targeted Therapy*
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Peptide YY / administration & dosage
-
Peptide YY / pharmacology
-
Peptide YY / therapeutic use*
-
Receptors, Gastrointestinal Hormone / agonists
-
Receptors, Gastrointestinal Hormone / metabolism
-
Receptors, Neuropeptide Y / antagonists & inhibitors
-
Receptors, Neuropeptide Y / metabolism
-
Signal Transduction / drug effects
-
Translational Research, Biomedical*
Substances
-
Anti-Obesity Agents
-
Appetite Depressants
-
Gastrointestinal Agents
-
Receptors, Gastrointestinal Hormone
-
Receptors, Neuropeptide Y
-
neuropeptide Y5 receptor
-
peptide YY receptor
-
Peptide YY